Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cost-Utility Analysis of Nivolumab in Adjuvant Treatment of Melanoma in France.
Bregman B, Teitsson S, Orsini I, Cotté FE, Amadi A, Moshyk A, Roze S, Gaudin AF. Bregman B, et al. Among authors: moshyk a. Dermatol Ther (Heidelb). 2020 Dec;10(6):1331-1343. doi: 10.1007/s13555-020-00446-z. Epub 2020 Sep 13. Dermatol Ther (Heidelb). 2020. PMID: 32920709 Free PMC article.
A matching-adjusted indirect comparison of combination nivolumab plus ipilimumab with BRAF plus MEK inhibitors for the treatment of BRAF-mutant advanced melanoma☆.
Tarhini AA, Toor K, Chan K, McDermott DF, Mohr P, Larkin J, Hodi FS, Lee CH, Rizzo JI, Johnson H, Moshyk A, Rao S, Kotapati S, Atkins MB. Tarhini AA, et al. Among authors: moshyk a. ESMO Open. 2021 Apr;6(2):100050. doi: 10.1016/j.esmoop.2021.100050. Epub 2021 Feb 6. ESMO Open. 2021. PMID: 33556898 Free PMC article.
Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
Dalle S, Mortier L, Corrie P, Lotem M, Board R, Arance AM, Meiss F, Terheyden P, Gutzmer R, Buysse B, Oh K, Brokaw J, Le TK, Mathias SD, Scotto J, Lord-Bessen J, Moshyk A, Kotapati S, Middleton MR. Dalle S, et al. Among authors: moshyk a. BMC Cancer. 2021 May 29;21(1):642. doi: 10.1186/s12885-021-08032-y. BMC Cancer. 2021. PMID: 34051732 Free PMC article. Clinical Trial.
Heterogeneity in Survival with Immune Checkpoint Inhibitors and Its Implications for Survival Extrapolations: A Case Study in Advanced Melanoma.
Federico Paly V, Kurt M, Zhang L, Butler MO, Michielin O, Amadi A, Hernlund E, Johnson HM, Kotapati S, Moshyk A, Borrill J. Federico Paly V, et al. Among authors: moshyk a. MDM Policy Pract. 2022 Mar 26;7(1):23814683221089659. doi: 10.1177/23814683221089659. eCollection 2022 Jan-Jun. MDM Policy Pract. 2022. PMID: 35356551 Free PMC article.
25 results